See prescribing and safety info including boxed warning. Vectibix ® blocks growth signals from getting to egfr receptors vectibix ® is a monoclonal antibody designed to latch on to egfr and block growth signals from reaching it Blocking signals may help stop the growth and survival of cancer cells. Binding results in internalization of the receptor, cell growth inhibition, induction of apoptosis, and decreased production of interleukin 8 and vascular. Epidermal growth factor receptor (egfr) inhibitors are valuable therapeutics in metastatic colorectal cancer (mcrc) Abstract cetuximab and panitumumab, as the highly effective antibodies targeting epidermal growth factor receptor (egfr), have clinical activity in the patients with metastatic colorectal cancer (mcrc)
These agents have good curative efficacy, but drug resistance also exists at the same time. Abstract panitumumab is a fully human monoclonal antibody targeting the epidermal growth factor receptor (egfr)
WATCH
